Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Antiandrogens assume a significant part in the therapy of prostate cancer, the most well-known cancer in men. The market for antiandrogens is extending in oncology with the improvement of novel treatments focusing on androgen receptor flagging pathways, including cutting edge antiandrogens and blend treatments, further developing endurance results and personal satisfaction for patients with cutting edge prostate cancer.
There is a developing interest for hormonal treatments containing antiandrogens in the management of androgen-related problems like hirsutism and PCOS in ladies. Combination treatments consolidating antiandrogens close by estrogen-progestin definitions or oral contraceptives are successful in overseeing hyperandrogenism and related side effects, driving market growth in ladies' wellbeing.
The antiandrogens market is seeing a shift towards skin plans for the treatment of androgenetic alopecia and skin break out, offering restricted transference and possibly further developed decency contrasted with oral medications. Effective antiandrogens, including spironolactone and flutamide, are acquiring prominence as adjunctive treatments in dermatology, adding to market development in this section.
Innovative work endeavors are centered around distinguishing and creating novel antiandrogen treatments with further developed adequacy and security profiles. Designated treatments like androgen receptor anatgonists, 5-alpha-reductase inhibitors, and double activity antiandrogens are being scrutinized for different androgen-related messes, driving advancement in the antiandrogens market.
Drug organizations are putting resources into accuracy medication approaches for the advancement of antiandrogen treatments customized to individual patient attributes like chemical receptor status, hereditary transformations, and treatment reaction. Customized treatment procedures mean to streamline helpful results, limit secondary effects, and work on persistent fulfillment in the antiandrogens market.
The antiandrogens market is growing worldwide with expanding awareness and analysis of androgen-related messes in developing markets. Drug organizations are zeroing in on market entrance systems, including geological extension, associations with neighborhood merchants, and special exercises, to profit by the developing interest for antiandrogen treatments in these locales.
Antiandrogens Market Highlights:
Antiandrogens Market Overview
Antiandrogens Market Size was valued at USD 5.19 Billion in 2022. The Antiandrogens market industry is projected to grow from USD 5.4 Billion in 2023 to USD 9.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.1% during the forecast period (2023 - 2032).The growing incidence of prostate cancer and the increased research and development efforts are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Antiandrogens Market Trends
- Growing cancer patients is driving the market growth
Market CAGR for antiandrogens is being driven by the rising number of cancer patients. According to GLOBOCAN data, 1,414,259 instances of prostate cancer, or 7.3% of all cancer cases globally, were reported in 2020. Because there is such a high incidence of prostate cancer worldwide, there is a high need for effective treatments, which fuels the market for androgen deprivation therapy. Prostate cancer is widespread among adults 65 and older, according to a report released by the American Cancer Society in January 2022. The market will thus be driven by the expanding elderly population, which will also increase demand for its therapies. In 2050, 15 billion people worldwide, up from 727 million today, will be over 65, according to World Population Prospects' estimates for 2020. Thus, an aging population is anticipated to fuel market expansion. Additionally, market expansion will be aided by major market participants' methods, including collaborations, distribution contracts, mergers, and acquisitions.
The prevalence of prostate cancer in men, androgenic alopecia (male pattern hair loss), benign prostatic hyperplasia, premature puberty in young guys, and hypersexuality are expected to rise throughout the forecast period, driving demand for antiandrogens. Additionally, the market for antiandrogens is anticipated to be driven by the growth in acne, amenorrhea (the absence of monthly cycles), hirsutism (excessive face or body hair), and polycystic ovarian syndrome in women. In the United States, there are 5.7 million individuals who suffer from hypersexuality condition, according to Sexual Health Matters. Over 95% of men in the United States experience hair loss each year, according to the American Hair Loss Association, which attributes this to androgenic alopecia, also known as common male pattern baldness. Anti-androgens are medications that attach to androgen receptors and prevent androgens from promoting the formation of tumors. Androgen receptor antagonists are another name for anti-androgens. Flutamide (Eulexin), Bicalutamide (Casodex), Enzalutamide (Xtandi), Apalutamide (Erleada), and Darolutamide (Nubeqa) are antiandrogen medications.Prostate cancer occurrences are increasing worldwide, and factors like product approvals, an aging population, increased R&D efforts, and strategies used by major market players, including collaborations, will all significantly boost market growth.Thus, driving the Antiandrogens market revenue.
Antiandrogens Market Segment Insights
Antiandrogens Type Insights
Based on type, the Antiandrogens market segmentation includes steroidal and nonsteroidal. The nonsteroidal segment dominated the market, accounting for 65% of market revenue. Anti-androgens are medications that attach to androgen receptors and prevent androgens from promoting the formation of tumors. Androgen receptor antagonists are another name for anti-androgens. Flutamide (Eulexin), Bicalutamide (Casodex), Enzalutamide (Xtandi), Apalutamide (Erleada), and Darolutamide (Nubeqa) are antiandrogen medications. Prostate cancer occurrences are increasing worldwide, and factors like product approvals, an aging population, increased R&D efforts, and strategies used by major market players, including collaborations, will all significantly boost market growth.
Antiandrogens Disease Indication Insights
Based on disease indication, the Antiandrogens market segmentation includes prostate cancer, benign prostatic hyperplasia, hirsutism, hyperandrogenism, and others. The prostate cancer segment dominated the market, accounting for 65% of market revenue. The older population has increased due to lower morbidity rates in affluent nations, making them more vulnerable to prostate cancer. Therefore, the prevalence of prostate cancer is influenced by a rise in the elderly population, sedentary lifestyles in affluent nations, and childhood obesity. As a result, there is a greater need and higher demand for prostate cancer therapies. The National Library of Medicine reports that in 2022, cancer will be responsible for 2,68 490 new cases and 34,500 fatalities (3.8% of all cancer-related deaths in males). The average age at diagnosis is 66 years, and both the incidence and death rate of prostate cancer rises with age globally.
Antiandrogens Distribution Channel Insights
Based on distribution channels, the Antiandrogens market segmentation includes hospital, retail, and online pharmacies. Online pharmacies category generated the most income. Patients can buy antiandrogens in a simple method through online pharmacies. Patients may order antiandrogens from the convenience of their homes, and the medications can be delivered right to their front door. Compared to hospital and retail pharmacies, online pharmacies frequently have lower costs for antiandrogens. This is because compared to conventional brick-and-mortar pharmacies, internet pharmacies do not have the same overhead expenses.
Figure 1: Antiandrogens Market, by Distribution channel, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Antiandrogens Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Antiandrogens market area will dominate this market, Prostate cancer, a serious problem in North America, is frequently treated with antiandrogens. The use of targeted medicines and combination therapy, among other recent advancements in cancer treatment, may have affected the market's expansion.
Further, the major countries studied in the market report are The US, Canada, German, France, Italy, Spain, UK, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: ANTIANDROGENS MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe has the second-largest market share for Antiandrogens. As the population of Europe ages, so does vulnerability to diseases like prostate cancer, for which antiandrogens are an important therapy option. The prevalence of prostate cancer is increasing across the continent, which has increased demand for antiandrogens and led to market growth. Furthermore, the German Antiandrogens market dominated, while the UK Antiandrogens market grew fastest in Europe.
From 2023 to 2032, the Asia-Pacific Antiandrogens Market will develop the quickest CAGR Applications of Antiandrogens. Advanced antiandrogen drugs have been introduced due to expanding medical research and development spending and bettering healthcare infrastructure. The creation of targeted medicines, combination treatments, and improved drug delivery techniques has been made possible through cooperative efforts between pharmaceutical corporations, research institutes, and healthcare practitioners. These developments improve patient outcomes and help the antiandrogens industry grow. Furthermore, China's Antiandrogens market had the highest market share. In contrast, the Asia-Pacific region's Antiandrogens market in India was the one that was growing the quickest.
Antiandrogens Key Market Players & Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Antiandrogens market grow even more. Important market developments include contractual agreements, new product releases, acquisitions and mergers, greater investments, and collaboration with other organizations. The Antiandrogens must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Antiandrogens to serve clients and expand the market sector. The Antiandrogens has provided some of the most important benefits recently. AstraZeneca Plc, and other major competitors in the Antiandrogens market are seeking to improve market demand by investing in R&D efforts.
AstraZeneca Plc is a pharmaceutical firm focusing on patients, guided by science. AstraZeneca Plc is committed to revolutionizing future healthcare by utilizing science's potential to benefit individuals, society, and the environment. AstraZeneca Plc is committed to providing a fantastic workplace. One where each person who chooses to work at our organization has the opportunity to benefit patients, society, and the environment positively. AstraZeneca Plc works to create a culture where everyone feels like they belong and is free to fulfill their potential, give their all, and contribute positively to the business.
Genentech's biotechnology business is committed to conducting ground-breaking research to find and provide treatments for patients with serious and life-threatening illnesses. The first targeted antibody for cancer and the first treatment for primary progressive multiple sclerosis are only two examples of their game-changing breakthroughs. They are proud of their distinguished past as the forerunners of scientific discoveries with a remarkable track record of enhancing people's lives. Nevertheless, their goals are higher and more audacious. They have joined forces in a daring effort to address the most difficult health issues facing humanity while benefiting society. Dependent upon everyone who works here having a pleasant experience, being engaged, and being resilient, they can provide patients with transforming medications. Their employees are the core of Genentech and the energy behind the advancement that provides vital new medications to those in need.
Key Companies in the Antiandrogens market include
-
Pfizer Inc.
-
Astellas Pharma Inc.
-
F. Hoffmann-La Roche Ltd.
-
AstraZeneca Plc
-
Abbott Laboratories
-
Takeda Pharmaceutical Company Limited
-
OSI Pharmaceuticals, Inc.
-
Genentech Inc.
-
Bristol-Myers Squibb Company
-
Novartis AG
-
Progenics Pharmaceuticals, Inc.,
-
ALZA Corporation
-
Sanofi SA
-
GlaxoSmithKline Plc
-
Amgen Inc
-
ANI Pharmaceuticals, Inc.
-
Others.
Antiandrogens Industry Developments
May 2023:Recent research has confirmed the harmful effects of second-generation antiandrogens on cognition and functioning processes. Thirteen,524 men with metastatic or nonmetastatic prostate cancer treated or not with abiraterone, darolutamide, apalutamide, or enzalutamide were included in 12 randomized clinical studies published between 2011 and 2020. Kevin T. Nead, MPhil, MD, MD Anderson Cancer Centre, University of Texas in Houston, and colleagues reported in JAMA Oncology that second-generation antiandrogen users had a substantially 2.1-fold greater risk of cognitive adverse effects than nonusers.
Antiandrogens Market Segmentation
Antiandrogens Type Outlook
-
Steroidal
-
Nonsteroidal
Antiandrogens Disease Indication Outlook
-
Prostate Cancer
-
Benign Prostatic Hyperplasia
-
Hirsutism
-
Hyperandrogenism
-
Others
Antiandrogens Disease Indication Outlook
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Antiandrogens Regional Outlook
-
North America
-
US
-
Canada
-
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
-
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
